Study guide
16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow
IJCAHPO Certified Retina Technician CRT
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview: Current CRT Requirements & Blueprint
Exam Overview: Current Requirements, Scope & Study Plan
2 Chapter 1: History Taking, Triage & Clinical Documentation
1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes
3 Chapter 2: Visual Assessment & Low Vision Rehabilitation
2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling
4 Chapter 3: Pupil Assessment & Visual Field Testing
3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring
5 Chapter 4: Tonometry & Ocular Motility
4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing
6 Chapter 5: Diagnostic Ophthalmic Ultrasound
5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry
7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing
6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG
8 Chapter 7: Ophthalmic Microbiology & Infection Control
7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection
9 Chapter 8: General Retinal Pharmacology & Therapeutics
8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification
10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity
9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening
11 Chapter 10: Surgical Assisting & Intravitreal Procedures
10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization
12 Chapter 11: Patient Services, Education & Clinical Care
11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals
13 Chapter 12: General Ocular Anatomy & Retinal Physiology
12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology
14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations
13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments
15 Chapter 14: Ophthalmic Optics & Lensometry
14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques
16 Chapter 15: Fundus Photography & Ophthalmic Angiography
15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management
17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)
16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow
18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance
17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal
16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow
Key Takeaways Explain This Topic AI
OCT-A detects temporal decorrelation from moving blood cells; it does not directly image vessel walls, plasma leakage, or dye transit time.
En face slabs are segmentation choices rather than physical dissections, and boundaries must be checked on structural B-scans with flow overlay.
Apparent flow in an outer-retinal slab can represent neovascular flow, projection, segmentation error, or motion; it never confirms CNV without artifact review and clinical interpretation.
Slow flow below the device threshold and attenuation from hemorrhage, fluid, pigment, or media opacity can create false flow voids or pseudo-nonperfusion.
Use comparable scan size and device settings for follow-up, correct fixation and motion where possible, and preserve both en face and cross-sectional data.
Last updated: September 2026
OCT Angiography Principles, Slabs, and Artifacts
Optical coherence tomography angiography (OCT-A) compares repeated B-scans at the same location. Static tissue produces similar backscatter, while moving erythrocytes change amplitude or phase and generate decorrelation. Algorithms convert that motion contrast into flow maps.
What OCT-A shows and does not show
OCT-A is noninvasive and depth-resolved. It can depict capillary networks, foveal avascular zone contour, neovascular complexes, and areas with reduced detectable flow. It does not directly show fluorescein leakage, pooling, staining, or transit time. Absence of signal does not prove absence of a vessel; flow may be too slow, too fast for the algorithm, attenuated, or outside the slab.
Algorithm names and scan speeds vary by manufacturer. Learn the device's quality metric, scan pattern, motion correction, and export conventions rather than assuming one platform's numbers apply to another.
Slab anatomy
Common displays include superficial and deep retinal plexuses, an outer-retinal slab, and choriocapillaris or deeper choroidal slabs. The exact boundaries differ among devices and can shift when edema, PED, atrophy, traction, or segmentation failure distorts anatomy.
Always inspect the structural B-scan with segmentation lines and flow overlay. An en face image without cross-sectional confirmation can place superficial vessels into a deeper slab or omit real flow.
Neovascular flow
The normal outer retina lacks intrinsic vessels, so genuine flow there is concerning for neovascular tissue. However, apparent outer-retinal flow may come from projection of superficial vessels onto reflective deeper tissue, incorrect slab boundaries, motion, or noise. Compare vessel shape with overlying plexuses, toggle projection-removal tools, adjust segmentation when authorized, and check structural location. The clinician integrates OCT-A with OCT fluid, examination, photography, FA, or ICG.
Do not tell the patient that any colored pixel confirms CNV. Likewise, absence of a visible network does not exclude activity when hemorrhage, slow flow, poor signal, or segmentation error is present.
Common artifacts
Projection: superficial vessel pattern appears in deeper slabs.
Motion: horizontal or vertical bands, duplicated vessels, or displacement from blinks and saccades.
Segmentation: boundaries cut through the wrong tissue, especially with PED, edema, or atrophy.
Shadowing or attenuation: hemorrhage, pigment, fluid, opacity, or lashes reduce signal and mimic nonperfusion.
Unmasking or hypertransmission: atrophy increases deeper signal and changes apparent choroidal texture.
Threshold artifact: slow flow falls below detection and appears absent.
Tail or decorrelation artifact: bright structures or motion extend signal beyond its true location.
Acquisition workflow
Confirm eye, scan size, fixation target, and clinical question.
Center the region and optimize focus, polarization, and signal using device instructions.
Reduce blink and motion without exhausting the patient.
Review every slab with structural B-scans and segmentation.
Repeat a poor scan when authorized and feasible, preserving the reason.
Use the same device and scan dimensions for serial quantitative comparison when possible.
Save en face images, flow overlays, and source structural data.
Quantitative measures such as vessel density or FAZ area are affected by scan size, magnification, axial length, segmentation, thresholding, and software version. Do not compare numbers across platforms as though they were interchangeable.
Clinical comparison
- Modality Strength Limitation
- Structural OCT Fluid and tissue architecture Does not directly map all perfusion
- OCT-A Depth-resolved motion contrast No leakage or transit; artifact-sensitive
- Fluorescein angiography Retinal filling and leakage over time Two-dimensional, intravenous dye
ICG angiography Choroidal circulation through pigment and some blood Intravenous dye; less retinal capillary detail
OCT-A is powerful when acquisition and artifact review are disciplined.
Acquisition strategy and cross-sectional confirmation
Select the ordered scan size and fixation target, optimize focus and polarization when available, and keep the patient aligned. Smaller fields generally provide denser sampling, while wider fields trade density for coverage; use the same protocol for follow-up unless the order changes. Review the motion-correction result rather than assuming it repaired blinking or saccades. Reacquire when possible if vessel doubling, horizontal displacement, fringe washout, or poor signal makes the slab unreliable.
Never interpret an en face slab alone. Scroll the B-scans with flow overlay to confirm that a signal lies in the expected tissue and is not projection from a superficial vessel. Inspect segmentation boundaries across pathology because fluid, pigment-epithelial detachment, atrophy, and traction can displace automated lines. Absence of visible flow does not exclude a lesion: slow flow, small caliber, shadowing, and threshold settings can produce false negatives. Conversely, a flow signal outside normal layers is not by itself proof of active neovascular disease. Save relevant slabs and B-scans and route the study for clinician interpretation.